TKIs linked to HBV reactivation

Cases of hepatitis B virus reactivation have occurred in patients who are chronic carriers of the virus after they received Bcr-Abl tyrosine kinase inhibitors, the TGA has warned. In its latest Medicines Safety Update it advises that patients who are carriers of HBV who require treatment with Bcr-Abl TKIs should be closely monitored for signs ...

Already a member?

Login to keep reading.

© 2021 the limbic